Showing 1151-1160 of 20877 results for "".
- Tucidinostat Plus R-CHOP Improves Outcomes in Double-Expressor DLBCLhttps://reachmd.com/news/tucidinostat-plus-r-chop-improves-outcomes-in-double-expressor-dlbcl/2486836/Key Takeaways Tucidinostat plus R-CHOP was associated with improved event-free survival versus placebo plus R-CHOP in newly diagnosed MYC/BCL2 double-expressor DLBCL. The tucidinostat regimen was also associated with a higher complete response rate at
- Gut Microbiome May Predict IBS Response to Rifaximin or Low FODMAPhttps://reachmd.com/news/gut-microbiome-may-predict-ibs-response-to-rifaximin-or-low-fodmap/2486829/Key Takeaways Both treatment groups had similar improvement in abdominal pain and bloating at five weeks. Baseline and follow-up stool microbiome profiles differed across low FODMAP responders, rifaximin responders, and non-responders. Breath
- Multifaceted Strategies for Hypertension Control in Low-Income Patientshttps://reachmd.com/news/multifaceted-strategies-for-hypertension-control-in-low-income-patients/2486840/Key Takeaways The trial reported 18-month changes in systolic blood pressure comparing the intervention and enhanced usual-care groups in low-income adults with hypertension. A low-cost, multifaceted, team-based care strategy—including protocol-based m
- Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patientshttps://reachmd.com/news/influenza-vaccination-and-cardiovascular-outcomes-in-high-risk-patients/2486818/Key Takeaways Influenza vaccination was associated with lower all-cause mortality and lower cardiovascular mortality in patients with ischemic heart disease or heart failure. Myocardial infarction risk was lower in vaccinated patients, whereas stroke a
- Rapid Blood Infection Test Fails To Improve Survivalhttps://reachmd.com/news/rapid-blood-infection-test-fails-to-improve-survival/2486815/Key Takeaways Rapid testing was not superior to standard susceptibility testing for 30-day clinical outcomes, including mortality, in gram-negative bloodstream infection. Faster overall antibiotic escalation or de-escalation was observed, along with mo
- Imaging Bests Exam in Detecting Nodal Metastases in High-Risk cSCChttps://reachmd.com/news/imaging-bests-exam-in-detecting-nodal-metastases-in-high-risk-cscc/2486802/Ultrasonography and computed tomography (CT) outperformed physical examination for detecting baseline nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC). Investigators for the prospective, multicenter diagnostic study evaluated baseline staging modalities for detecting
- Atezolizumab Plus FOLFOX Improves DFS in Stage III dMMR Colon Cancerhttps://reachmd.com/news/atezolizumab-plus-folfox-improves-dfs-in-stage-iii-dmmr-colon-cancer/2486784/Key Takeaways The phase 3 randomized trial compared atezolizumab plus mFOLFOX6 with mFOLFOX6 alone after resection in stage III dMMR colon cancer. Disease-free survival was higher and recurrence or death was lower with the atezolizumab-containing regim
- Smart Inhaler Feedback In Children With Uncontrolled Asthmahttps://reachmd.com/news/smart-inhaler-feedback-in-children-with-uncontrolled-asthma/2486786/Key Takeaways Several asthma control measures improved over time, but no significant between-group difference was observed. The intervention compared Respiro app-based reminders and personalized inhalation feedback with monitoring without feedback in c
- Vixarelimab Trial Reports Itch and Lesion Benefit in Prurigo Nodularishttps://reachmd.com/news/vixarelimab-trial-reports-itch-and-lesion-benefit-in-prurigo-nodularis/2486772/Key Takeaways Greater week 16 itch reduction was observed with vixarelimab than placebo, with the clearest effects in the 540-mg and 360-mg groups. Clinically meaningful WI-NRS responder rates and PN-IGA clear or almost clear responses were higher with
- AACR Release Highlights Pathomics Model For NSCLC Immunotherapy Responsehttps://reachmd.com/news/aacr-release-highlights-pathomics-model-for-nsclc-immunotherapy-response/2486773/Key Takeaways Path-IO applied to routine pathology slides in metastatic NSCLC was reported to separate patients into higher- and lower-risk groups with different outcomes. Investigators observed stronger discrimination than PD-L1 in both discovery and